GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.15M | -575.50K | 17.20K | 109.20K | 207.60K |
| Total Other Revenue | 861.00K | 806.00K | 738.90K | 773.40K | 814.90K |
| Total Revenue | -293.90K | 230.60K | 756.10K | 882.60K | 1.02M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -293.90K | 230.60K | 756.10K | 882.60K | 1.02M |
| SG&A Expenses | 6.67M | 6.37M | 5.96M | 6.10M | 6.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.63M | 14.05M | 13.16M | 15.28M | 17.56M |
| Operating Income | -14.93M | -13.82M | -12.40M | -14.40M | -16.53M |
| Income Before Tax | -17.89M | -15.88M | -13.54M | -14.93M | -16.44M |
| Income Tax Expenses | 5.80K | 100.00 | -5.20K | 1.00K | 7.50K |
| Earnings from Continuing Operations | -17.90 | -15.88 | -13.53 | -14.93 | -16.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.90M | -15.88M | -13.53M | -14.93M | -16.45M |
| EBIT | -14.93M | -13.82M | -12.40M | -14.40M | -16.53M |
| EBITDA | -14.79M | -13.61M | -12.12M | -13.91M | -15.82M |
| EPS Basic | -0.09 | -0.09 | -0.09 | -0.11 | -0.14 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.06 | -0.07 | -0.09 |
| EPS Diluted | -0.09 | -0.09 | -0.09 | -0.11 | -0.14 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.06 | -0.07 | -0.09 |
| Average Basic Shares Outstanding | 782.97M | 699.89M | 605.08M | 545.44M | 485.79M |
| Average Diluted Shares Outstanding | 782.97M | 699.89M | 605.08M | 545.44M | 485.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |